Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.
You may also be interested in...
Epizyme Builds A Cancer Company At Mach Speed
Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.
Ligand Takes Out Neurogen For At Least $11 Million
Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.
Ligand Takes Out Neurogen For At Least $11 Million
Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.